Archive · 27 Oct 2025
Novartis to Acquire Avidity for $12 Billion
Imagine a big medicine company, Novartis, wants to buy another company, Avidity Biosciences, for a lot of money – $12 billion!
This is like when you trade your toys to buy a bigger, better one.
Avidity makes special medicines to help people with rare muscle problems.
Novartis wants to buy Avidity to get those medicines and make them better.
The deal is expected to finish in the first half of 2026.
This means Novartis will add Avidity's work to its own, hopefully helping many people who have these problems.
Both companies are committed to researching and developing innovative medicines.
This move will allow Novartis to target and treat diseases in a more effective way.
Novartis will acquire Avidity Biosciences for approximately $12 billion.
Avidity stockholders will receive $72 per share in cash.
The acquisition aims to expand Novartis's focus on rare muscle disorders.
Avidity is developing treatments for various muscle disorders.
Deal helps Novartis establish a stronger foothold in the U.S. market.
- Who
- Novartis and Avidity Biosciences
- What
- Novartis agreed to acquire Avidity Biosciences
- When
- Announced Sunday, October 27, 2025
- Where
- United States
- Why
- To strengthen its presence in the rare disease landscape and address the impending patent cliff.
Novartis' Perspective
Avidity's Perspective
Deal Value
Novartis' Perspective
Sees the acquisition as a strategic move to address the impending patent cliff and strengthen its focus on rare disease treatments.
Avidity's Perspective
Avidity's stockholders will receive $72 per share in cash.
- Acquisition Target
- Avidity Biosciences
- Acquirer
- Novartis
- Deal Value
- $12 billion
- Closing Date (Expected)
- First half of 2026
- Avidity's Focus
- Rare muscle disorders
- Avidity Share Price Premium
- 46% over Friday's closing price
